Francisca Vazquez PhD
@vazquezf.bsky.social
Cofounder and Director | Cancer Dependency Map Consortium #depmap | Cancer Target Discovery @Broad Institute
https://target-discovery.depmap.org/
https://target-discovery.depmap.org/
(3/3) This is a great example of how DepMap enables discoveries beyond sequencing, revealing novel therapeutic targets like PELO
This was a wonderful close collaboration with Ed Chan’s team. Huge thanks to Patricia Borck, Isabella Boyle & our amazing team!
This was a wonderful close collaboration with Ed Chan’s team. Huge thanks to Patricia Borck, Isabella Boyle & our amazing team!
February 6, 2025 at 1:07 PM
(3/3) This is a great example of how DepMap enables discoveries beyond sequencing, revealing novel therapeutic targets like PELO
This was a wonderful close collaboration with Ed Chan’s team. Huge thanks to Patricia Borck, Isabella Boyle & our amazing team!
This was a wonderful close collaboration with Ed Chan’s team. Huge thanks to Patricia Borck, Isabella Boyle & our amazing team!
(2/2)
MSI-H → TTC37 mutations disrupt SKI function
9p21.3 deletion → FOCAD loss destabilizes the SKI complex
SKIc disruption -> PELO dependency
Both MSI-H and 9p21.3 deletion are frequent in many adult tumors making PELO a potential target for a large patient population
MSI-H → TTC37 mutations disrupt SKI function
9p21.3 deletion → FOCAD loss destabilizes the SKI complex
SKIc disruption -> PELO dependency
Both MSI-H and 9p21.3 deletion are frequent in many adult tumors making PELO a potential target for a large patient population
February 6, 2025 at 1:07 PM
(2/2)
MSI-H → TTC37 mutations disrupt SKI function
9p21.3 deletion → FOCAD loss destabilizes the SKI complex
SKIc disruption -> PELO dependency
Both MSI-H and 9p21.3 deletion are frequent in many adult tumors making PELO a potential target for a large patient population
MSI-H → TTC37 mutations disrupt SKI function
9p21.3 deletion → FOCAD loss destabilizes the SKI complex
SKIc disruption -> PELO dependency
Both MSI-H and 9p21.3 deletion are frequent in many adult tumors making PELO a potential target for a large patient population